Table 1

Clinical data
Parameter Values Description and references
Weibull survival model of PFS in the Control strategy Scale = 0.1559; [11]
Shape = 1.045;
r2 = 0.976
Weibull survival model of OS for supportive care Scale = 0.04006;
Shape = 1.156; [20]
r2 = 0.9898
Weibull survival model of OS for 2nd-line chemotherapy Scale = 0.03897; [20]
Shape = 1.509;
r2 = 0.981
HR of PFS for the Gefitinib strategy in patients with an EGFR mutation 0.17 (95% CI:0.07–0.42) [11]
Frequency of EGFR mutations 50% (range: 8%–70%)* [11]
Proportion of patients receiving 2nd-line chemotherapy 56.6% (range: 26%–72%)* [5-10]
Frequency of follow-up
 0–2 years Once per four months [26]
 after 2 years Once per year [26]
Probability of SAEs in the Gefitinib strategy 7% (range: 5.25%–8.75%)* [11]
Probability of SAEs in the Control strategy 3% (range: 2.25%–3.75%)* [11]
Probability of SAEs using platinum-based chemotherapy 80% (range: 60%–100%)* [27]

* The range was assumed for one-way sensitivity analysis.

Zhu et al.

Zhu et al. BMC Cancer 2013 13:39   doi:10.1186/1471-2407-13-39

Open Data